Beam Therapeutics

Beam Therapeutics starts dosing in phase 1/2 trial of BEAM-201 in relapsed, refractory T-ALL/T-LL
Beam Therapeutics starts dosing in phase 1/2 trial of BEAM-201 in relapsed, refractory T-ALL/T-LL
Benzinga
Beam Therapeutics
clinical trials
CAR-T
BEAM-201
T-ALL
T-LL
Flag link:
Gene Editing Therapeutics Could Hit the Market in 2023
Gene Editing Therapeutics Could Hit the Market in 2023
BioSpace
gene editing
CRISPR Therapeutics
Vertex Pharmaceuticals
Intellia Therapeutics
Editas Medicine
Beam Therapeutics
Flag link:
A stealth biotech startup is quietly advancing a new drugmaking tool from David Liu’s lab
A stealth biotech startup is quietly advancing a new drugmaking tool from David Liu’s lab
BioPharma Dive
startups
biotech
Beam Therapeutics
Prime Medicine
Resonance Medicine
David Liu
Flag link:
Beam jumps back into off-the-shelf CAR-T race after FDA lifts clinical hold
Beam jumps back into off-the-shelf CAR-T race after FDA lifts clinical hold
Fierce Biotech
Beam Therapeutics
FDA
CAR-T
clinical trials
BEAM-201
Flag link:
Beam-linked startup launches with an eye on the next generation of RNA drugs
Beam-linked startup launches with an eye on the next generation of RNA drugs
BioPharma Dive
Orbital Therapeutics
Beam Therapeutics
RNA
R&D
Flag link:
Beam details reasons for FDA hold on base editing cancer therapy
Beam details reasons for FDA hold on base editing cancer therapy
BioPharma Dive
Beam Therapeutics
FDA
gene editing
cancer
Flag link:
Beam reveals what tripped up its base-edited, off-the-shelf CAR-T as it tries to clear FDA hold
Beam reveals what tripped up its base-edited, off-the-shelf CAR-T as it tries to clear FDA hold
Endpoints
Beam Therapeutics
FDA
CAR-T
Flag link:
FDA halts testing of Beam’s base editing cancer therapy
FDA halts testing of Beam’s base editing cancer therapy
BioPharma Dive
Beam Therapeutics
clinical trials
FDA
gene editing
CRISPR
Flag link:
Why Pfizer's Deal With Beam Therapeutics Is a Smart Move
Why Pfizer's Deal With Beam Therapeutics Is a Smart Move
Motley Fool
Pfizer
Beam Therapeutics
gene editing
Flag link:
Pfizer expands into gene editing with Beam research deal
Pfizer expands into gene editing with Beam research deal
BioPharma Dive
Pfizer
Beam Therapeutics
MRNA
gene editing
Flag link:
Biotech M&A tracker: After hitting new heights, deals have slowed down. Here are the latest.
Biotech M&A tracker: After hitting new heights, deals have slowed down. Here are the latest.
BioPharma Dive
M&A
Bayer
Sanofi
Amgen
uniQure
MorphoSys
Xeris Pharmaceuticals
Relay Therapeutics
Merck
Beam Therapeutics
Jazz Pharmaceuticals
Flag link:
2 Winners for a Drug Development Future That Looks Nothing Like the Past
2 Winners for a Drug Development Future That Looks Nothing Like the Past
Motley Fool
genomics
Pacific Biosciences
Beam Therapeutics
Flag link:
Gene editing biotech Beam adds to drug delivery stable with $120M GuideTx buy
Gene editing biotech Beam adds to drug delivery stable with $120M GuideTx buy
Fierce Biotech
Beam Therapeutics
gene editing
drug delivery
Flag link:
Beam, Verve stockpile cash as investors bank on gene editing progress
Beam, Verve stockpile cash as investors bank on gene editing progress
BioPharma Dive
Beam Therapeutics
Verve Therapeutics
gene editing
funding
Flag link:
This Startup Might Finally Cure Sickle Cell Disease—After A Century Of Racist Neglect
This Startup Might Finally Cure Sickle Cell Disease—After A Century Of Racist Neglect
Forbes
Beam Therapeutics
sickle cell disease
racism
Flag link:
Magenta, Beam partner to explore use of antibody-based conditioning drug for gene therapies
Magenta, Beam partner to explore use of antibody-based conditioning drug for gene therapies
MedCity News
Magenta Therapeutics
Beam Therapeutics
MGTA-117
gene therapy
sickle cell disease
beta thalassemia
Flag link:
Covid-19 stalls biotech flotations
Covid-19 stalls biotech flotations
EP Vantage
COVID-19
IPOs
Revolution Medicines
Black Diamond Therapeutics
Passage Bio
Beam Therapeutics
Schrödinger
Flag link:
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Xconomy
IPOs
Beam Therapeutics
gene editing
Flag link:
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
Yahoo/Benzinga
earnings
Forty Seven
Jounce Therapeutics
Catalyst Biosciences
Kodiak Sciences
Adverum Biotechnologies
IPOs
Beam Therapeutics
Flag link:
This Start-up Might Be the Next Gene Editing IPO
This Start-up Might Be the Next Gene Editing IPO
Motley Fool
gene editing
Beam Therapeutics
IPOs
CRISPR
Flag link:

Pages